In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary factor for portal hypertension (PH) development. Hepatic stellate cells (HSCs) play a major role increasing IHVR because, when activated, they are contractile and promote fibrogenesis. Protease-activated receptors (PARs) can activate HSCs through thrombin and factor Xa, which are known PAR agonists, and cause microthrombosis in liver microcirculation. This study investigates the effects of the oral anticoagulant, rivaroxaban (RVXB), a direct antifactor Xa, on HSC phenotype, liver fibrosis (LF), liver microthrombosis, and PH in cirrhotic rats. Hepatic and systemic hemodynamic, nitric oxide (NO) bioavailability, LF, HSC activation, and microthrombosis were evaluated in CCl 4 and thioacetamide-cirrhotic rats treated with RVXB (20 mg/kg/day) or its vehicle for 2 weeks. RVXB significantly decreased portal pressure (PP) in both models of cirrhosis without changes in portal blood flow, suggesting a reduction in IHVR. RVXB reduced oxidative stress, improved NO bioavailability, and ameliorated endothelial dysfunction. Rivaroxaban deactivated HSC, with decreased alpha-smooth muscle actin and mRNA expression of other HSC activation markers. Despite this marked improvement in HSC phenotype, no significant changes in LF were identified. RVXB markedly reduced fibrin deposition, suggesting reduced intrahepatic microthrombosis. Conclusion: RVXB decreases PP in two rat models of cirrhosis. This effect is mostly associated with decreased IHVR, enhanced NO bioavailability, HSC deactivation, and reduced intrahepatic microthrombosis. Our findings suggest that RVXB deserves further evaluation as a potential treatment for cirrhotic PH. (HEPATOLOGY 2017;65:2031-2044.
P ortal hypertension (PH) is one of the main complications of cirrhosis. The increase in portal pressure (PP) is mainly attributed to an increased resistance to portal blood flow (PBF), derived from both augmented hepatic vascular tone and architectural alterations of the liver microcirculation. (1, 2) Hepatic stellate cell (HSC) activation plays a major role in both pathophysiological abnormalities.
Indeed, activated HSCs are key players increasing hepatic vascular tone and also synthesizing excessive extracellular matrix (ECM) components. (3) Proteaseactivated receptors (PARs) (4) (5) (6) (7) (8) are a group of Gprotein-coupled receptors. Molecular cloning has identified four different PARs: PAR1, PAR3, and PAR4, which can be activated by thrombin, and PAR2, which can be activated by factor Xa and trypsin. In healthy Abbreviations: Ach, acetylcholine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cGMP, cyclic guanosine monophosphate; col1a, collagen type I alpha; DHE, dihydroethidium; ECM, extracellular matrix; eNOS, endothelial nitric oxide synthase; eNOS-P, eNOS phosphorylation; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GBSS, Gey's balanced salt solution; HR, heart rate; HSCs, hepatic stellate cells; IHC, immunohistochemistry; IHVR, intrahepatic vascular resistance; KCs, Kupffer cells; LF, liver fibrosis; LMWH, low-molecular-weight heparins; MAQP, mean arterial pressure; NO, nitric oxide; O 2 -, superoxide; PAR, protease-activated receptors; PBF, portal blood flow; pdgfrb, platelet-derived growth factor receptor beta; PH, portal hypertension; PP, portal pressure; RhoA, Ras homolog gene family, member A; RVXB, rivaroxaban; a-SMA, alpha-smooth muscle actin; TAA, thioacetamide; TEM, transmission electron microscopy; tgfb, transforming growth factor beta; timp, tissue inhibitor of metalloproteinase; vWF, von Willebrand factor.
livers, PARs are expressed in several cells, such as HSCs, endothelial cells and Kupffer cells (KCs), (9) and represent one of the main activation pathways of HSCs and increase inflammatory cell recruitment in cirrhosis.
Interestingly, human livers undergoing acute and chronic injury have increased PAR expression. Furthermore, thrombin and factor Xa are also increased in cirrhosis, (10) (11) (12) and it has been suggested that increased levels of thrombin may lead to clot formation and occlusion of small intrahepatic veins and sinusoids, further aggravating the increased intrahepatic vascular resistance by causing parenchymal extinction and vascular distortion. (13, 14) Several studies have recently shown beneficial effects of PAR inhibition (15) and inhibition of the coagulation cascade in liver fibrosis, (16, 17) including up-regulation of nitric oxide (NO) levels through endotheliumdependent mechanisms. (18) Moreover, we have recently shown beneficial effects of enoxaparin, a lowmolecular-weight heparin (LMWH) with anti-Xa and antithrombin effect, in two different models of cirrhosis. (18) Rivaroxaban is an oral direct inhibitor of factor Xa, a key coagulation factor in thrombin generation and clot formation. In thromboembolic disease, randomized phase III clinical trials have demonstrated that oral factor Xa inhibitors had similar efficacy to standard therapy and were associated with significantly reduced risk of major bleeding. (19) The current study aimed at evaluating the effects of the direct oral anticoagulant, rivaroxaban (RVXB), in the hepatic and systemic hemodynamic NO pathway, liver fibrosis (LF), and microthrombosis in two different rat models of cirrhosis.
Materials and Methods

INDUCTION OF CIRRHOSIS BY CCl 4 AND BY THIOACETAMIDE
CCl 4
Wistar rats (50-75 g) received CCl 4 by inhalation three times a week to induce cirrhosis. Phenobarbital (0.3 g/L) was added to the drinking water as described. (20) When animals developed ascites, after approximately 14-18 weeks of CCl 4 inhalation, phenobarbital and CCl 4 administration was stopped.
Thioacetamide
Sprague Dawley rats (150-200 g) received thioacetamide (TAA; Sigma-Aldrich, Spain) dissolved in normal saline by intraperitoneal injection twice a week at a dose of 250 mg/kg for 12 weeks.
Animals were kept in environmentally controlled animal facilities at the Institut d'Investigacions Biomè-diques August Pi i Sunyer (IDIBAPS). All experiments were approved by the Laboratory Animal Care and Use Committee of the University of Barcelona (Barcelona, Spain) and were conducted in accord with European Community guidelines for protection of animals used for experimental and other scientific purposes (EEC Directive 86/609).
RVXB TREATMENT
Cirrhotic rats were randomized to receive RVXB (20 mg/kg/day) or its vehicle administered orally by gavage once a day for 2 weeks. Treatment started 1 week after development of ascites in the CCl 4 model and immediately after stopping the intraperitoneal injection of TAA in the second model. Experiments were performed 1 hour after the last RVXB dose or its vehicle. Treatments were prepared by a third person, and experimental studies were performed blindly.
IN VIVO HEMODYNAMIC STUDY
Rats were anesthetized with ketamine (100 mg/kg body weight, Imalgene 1000; Merial) plus midazolam (5 mg/kg body weight; Laboratorio Reig Jofr e, S.A., Spain) intraperitoneally, fastened to a surgical board, and maintained at a constant temperature of 37 6 0.58C (continuously monitored throughout the experiment). A tracheotomy and cannulation with a PE-240 catheter (Portex) was performed in order to maintain adequate respiration during anesthesia. Indwelling catheters made of polyethylene tubing (PE-50; Portex, UK) were placed into the femoral artery to measure mean arterial pressure (MAP; mm Hg) and heart rate (HR; beats per minute), and to the ileocolic vein to measure PP (mm Hg). PBF (mL/min) was measured with a nonconstrictive perivascular ultrasonic transittime flow probe (2PR, 2-mm diameter; Transonic Systems Inc., USA) placed around the portal vein just before its entrance in the liver, avoiding the measurement of most portal-collateral blood flow. The flow probe and pressure transducers were connected to a Powerlab (4SP) linked to a computer using Chart v5.5.6 for Windows software (AD Instruments, Australia). Intrahepatic vascular resistance (IHVR) was calculated as PP/PBF. Hemodynamic data were collected after a 20-minute stabilization period. At the end of the in vivo hemodynamic study, serum samples from cirrhotic rats were collected to subsequently evaluate alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and albumin, all by standard protocols. Experiments and data collection were performed blindly.
MEASUREMENT OF THE CELLULAR SUPEROXIDE CONTENT IN LIVER TISSUE
In situ superoxide (O 2 -) levels were evaluated as described. (21) Briefly, the oxidative fluorescent dye dihydroethidium (DHE; Molecular Probes, USA) was used in fresh liver cryosections (10 lm) obtained from CCl 4 -cirrhotic rats treated with RVXB (n 5 3) or vehicle (n 5 3). Six fields from each slide at 203 were randomly selected. Fluorescent images were obtained with a fluorescent microscope (Olympus) and quantitative analysis was performed with ImageJ 1.33u software (National Institutes of Health, Bethesda, MD). (18) 
CYCLIC GUANOSINE MONOPHOSPHATE LEVELS
Measurements of cyclic guanosine monophosphate (cGMP), a secondary marker of NO bioavailability, were performed in liver homogenates from vehicle or RVXB-treated CCl 4 -cirrhotic rats by enzyme immunoassay (Cayman Chemical Co., USA) as described. (22) 
EVALUATION OF ENDOTHELIAL FUNCTION
In CCl 4 -cirrhotic rats, after the in vivo hemodynamic measurements, livers were quickly isolated and perfused by a flow-controlled perfusion system as described. (23) The perfused rat liver preparation was allowed to stabilize for 20 minutes before vasoactive substances were added. The intrahepatic microcirculation was preconstricted by adding the a 1 -adrenergic agonist, methoxamine (10 -4 mol/L; Sigma-Aldrich), to the reservoir. After 5 minutes, concentrationresponse curves to cumulative doses of acetylcholine (Ach; Sigma-Aldrich) were evaluated. The concentration of Ach was increased by 1 log unit every 1.5-minute interval. Responses to Ach were calculated as the percentage change in portal perfusion pressure. (24) The gross appearance of the liver, stable perfusion pressure, bile production over 0.4 lL/min/g of liver, and a stable buffer pH (7.4 6 0.3) were monitored during this period. IHVR was also calculated in this portal-flow-controlled perfusion system.
SIRIUS RED STAINING
All livers from cirrhotic rats were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with 0.1% Sirius Red, photographed using a microscope equipped with a digital camera, and analyzed. Ten fields from each slide at 53 were randomly selected, and the red-stained area per total area was measured using AxioVision software. (25) Values are expressed as the mean of 10 fields taken from vehicleand RVXB-treated rats.
HEPATIC HYDROXYPROLINE CONTENT
Hydroxyproline content was assessed with the Hydroxyproline Colorimetric Assay Kit (BioVision, USA), following the manufacturer's instruction. Briefly, liver tissues were homogenized in dH 2 O. HCl (12M) was added to the homogenate and samples were incubated at 1208C for 3 hours. Kit reagents were added and absorbance at 560 nm was read in the plate reader and expressed as lg of hydroxyproline/mg liver.
WESTERN BLOTTING
Expression of alpha-smooth muscle actin (a-SMA), desmin, 3-nitrotyrosinated proteins, collagen, fibrinogen, endothelial nitric oxide synthase (eNOS) phosphorylation (eNOS-P), eNOS total, Ras homolog gene family, member A (RhoA), moesin, and phosphorylatedmoesin was determined by western blotting in hepatic samples as described. (26, 27) Briefly, snap-frozen liver samples were used and processed by sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and nitrocellulose membranes. The following antibodies were used: a-SMA (1:1,000; Sigma-Aldrich); desmin (1:1,000; Dako, USA); 3-nitrotyrosine (1:1,000; Cayman Chemical); collagen (1:1,000; Millipore, Spain); fibrinogen (1:1,000; Nordic-MUbio, The Netherlands); eNOS-P at Ser 1176 (1:1,000; Cell Signaling Technology, USA); eNOS (1:1,000; BD Transduction Laboratories, USA); RhoA (1:1,000; Santa Cruz Biotechnology, USA); moesin (1:200; Santa Cruz Biotechnology); and phosphorylated moesin (1:200; Santa Cruz Biotechnology). Thereafter, membranes were incubated with the corresponding secondary peroxidase-coupled antibody (Santa Cruz Biotechnology). Blottings were developed with enhanced chemiluminiscence (Millipore). Intensities of the digital detected bands were evaluated densitometrically using Multi Gauge (V2.1; Fujifilm, Spain).
Hepatic fibrin deposits were determined by western blotting using an antifibrinogen antibody, which detects fibrinogen epitopes preserved in the insoluble fibrin deposits, as described. (28, 29) Blottings were stained with Ponceau or anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase; 1:1,000; Santa Cruz Biotechnology) antibodies to show equal loading.
IMMUNOHISTOCHEMISTRY
Immunostaining of paraffin-embedded liver sections was performed with anti-a-SMA (1:1,200; Dako), antidesmin (1:50; Dako), antifibrinogen (1:1,200; Dako), anti-CD68 (1:100; Serotec, UK) or phosphatebuffered saline as a negative control. Bound antibodies were visualized using with Dako Real Envision Detection System Peroxidase/DAB1, and slides were counterstained with hematoxylin.
For a-SMA, desmin, and fibrinogen quantification, a point grid was placed over the slide pictures and the number of positive cells that collocate with the dots of the grid was counted. This value is expressed as a percentage of the total grid dots of the slide. (18, 20) Counting was done by two researchers blindly. Fifteen slide pictures were counted in each liver. For CD68, positive cells were counted per slide.
IMMUNOFLUORESCENCE
Optimal cutting temperature sections were fixed with methanol and blocked in 10% goat serum. Immunostaining was performed with anti-von Willebrand factor (vWF; 1:400; Dako, UK), anti-a-SMA (1:1,200; Sigma-Aldrich), and antifibrinogen (1:800; Dako). 555 Alexa antibody (1:300; Life Technologies, USA) was used as a secondary antibody. Imaging was done using a fluorescent microscope (Olympus, Japan). Fourteen fields were quantified in each liver with ImageJ 1.33u software (National Institutes of Health).
ISOLATION OF TOTAL RNA AND REAL TIME RT-PCR
Total RNA was isolated from liver tissues using TRIzol reagent (Invitrogen, USA), according to manufacturer's protocol. Hepatic mRNA expression of a-sma, collagen type I alpha (col1a) 1, col1a2, platelet-derived growth factor receptor beta (pdgfrb), tissue inhibitor of metalloproteinase (timp) 1, timp2, and transforming growth factor beta (tgfb) was analyzed by real-time PCR using predesigned gene expression assays and reported relative to endogenous control gapdh (Applied Biosystems, USA). All PCR reactions were performed in duplicate, using nuclease-free water as no template control.
ISOLATION OF HSCs AND CHARACTERIZATION
Primary CCl 4 -cirrhotic HSCs were isolated from cirrhotic rats as described. (30) Briefly, livers were perfused for 10 minutes at a flow rate of 20 mL/min at 378C with Gey's balanced salt solution (GBSS) with 0.6% heparin and then 30 minutes at a flow rate of 5 mL/min at a 378C with 0.02% collagenase A, 0.005% DNAse, and 0.16% pronase in GBSS. The resultant digested liver was excised and in vitro digestion was performed at 378C with 0.013% collagenase, 0.01% DNAse, and 0.004% pronase in GBSS. Cells were passed through nylon filters (100 lm) and centrifuged at 50g for 5 minutes. The dispersed cells were fractionated by density gradient centrifugation using Histodenz (SigmaAldrich). Cells were grown in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin/streptomycin, and 1% amphotericin B. Results using primary cirrhotic HSCs were derived from triplicates from three independent isolations. Effects of RVXB on HSC phenotype were determined through gene expression analysis of asma, col1a1, and pdgfrb, and HSC apoptosis was analyzed by cleaved caspase-3 protein expression (1:1,000; Cell Signaling Technology) by western blotting.
HSC ACTIVATION BY THROMBIN AND RVXB
HSCs isolated from control rats were treated in vitro with thrombin (1 and 5 U/mL for 24 hours; SigmaAldrich) or vehicle and with RVXB (25, 50, or 100 ng/mL; Bayer) or vehicle for 24 hours, and HSC activation markers were analyzed (a-sma, col1a1, and pdgfrb) by real-time RT-PCR.
TRANSMISSION ELECTRON MICROSCOPY
In a subgroup of TAA-cirrhotic rats treated with vehicle (n 5 4) or RVXB (n 5 4), after the in vivo hemodynamic measurements, livers were perfused through the portal vein with fixation solution containing 2.5% glutaraldehyde, 2% paraformaldehyde, 0.02 g/ mL of sucrose, and 0.02 M of CaCl 2 in 0.2 M of cacodylate buffer. Liver sections were fixed with 1% osmium in cacodylate buffer and, after dehydration in acetone gradients, embedded in Spurr resin. Ultrathin sections (50 nm) were counterstained with uranyl acetate and lead citrate. Twenty representative micrographs per animal were taken at 6,0003 and 3,0003 using a JEOL J1010 microscope and an ORIUS camera (Gatan Inc., Roper Technologies, USA). The presence of basal membrane in the space of Disse and the presence of hepatocyte projections in liver sinusoids were evaluated as indicators of correct liver sinusoidal architectural assembly in 6,0003 micrographs. These parameters were represented as a percentage of all the liver sinusoids analyzed. The number of HSCs per micrograph and the collagen content analyzed in a semiquantitative manner were evaluated in 3,0003 micrographs.
STATISTICAL ANALYSIS
Statistical analysis was performed with the SPSS 19.0 for Windows statistical package (SPSS, Inc., USA). All results are expressed as mean 6 SEM. Comparisons between groups were performed using the Student t test for unpaired data, one-sample t test, or with Mann-Whitney U test, when adequate. Results were considered significant when P < 0.05.
Results
RVXB IMPROVES IHVR AND DECREASES PP IN TWO DIFFERENT EXPERIMENTAL MODELS OF CIRRHOSIS IN THE RAT
RVXB-treated CCl 4 -cirrhotic rats had a significant lower PP value than vehicle-treated rats (Fig. 1A,B) . Given that O 2 -can decrease NO bioavailability, we evaluated cGMP as a marker of NO bioavailability. cGMP levels were increased markedly in RVXB-treated cirrhotic rats (Fig. 1C) . Interestingly, there were no differences in eNOS and eNOS-P at Ser 1176 between groups (Fig.  1D) , suggesting that RVXB increases NO bioavailability mainly by decreasing O 2 -levels. Because one of the main cells producing O 2 -within the liver are KCs, we analyzed CD68-positive cells within liver tissue and observed that RVXB-treated rats had less CD68-positive cells both in CCl 4 -(-19%) and TAAcirrhotic rats (-23%; Fig. 1E ).
EFFECT OF RVXB ON LIVER SINUSOIDAL ENDOTHELIAL DYSFUNCTION IN CIRRHOTIC RATS
CCl 4 -cirrhotic rats treated with RVXB have greater vasodilatory response to Ach, suggesting an improvement in endothelial dysfunction. However, probably attributed to the high variability observed among animals, this improvement was not statistically significant ( Fig. 2A; P 5 0. 2). To further study the potential beneficial effects of RVXB on endothelial function, vWF, a marker of endothelial capillarization and dysfunction, was analyzed. RVXB-treated cirrhotic rats had significantly lower vWF expression in both cirrhotic models (-62% in CCl 4 and -70% in TAA-cirrhotic rats; Fig.  2B ), further pointing to improved endothelial phenotype.
EFFECT OF RVXB ON LIVER SINUSOID ARCHITECTURE IN CIRRHOTIC RATS
The effect of RVXB on liver sinusoidal architecture was evaluated by transmission electron microscopy (TEM) in TAA-cirrhotic rats. We analyzed the absence of basal membrane in the space of Disse and the presence of hepatocyte projections in liver sinusoids. RVXB-treated TAA-cirrhotic rats had less formation of basal membrane and increased presence of projections in hepatocytes within liver sinusoids than vehicle-treated TAA-cirrhotic rats (Fig. 2C) . These data suggest that RVXB may improve liver sinusoidal architecture assembly.
EFFECT OF RVXB ON LIVER FIBROSIS IN CIRRHOTIC RATS
As expected, CCl 4 -and TAA-cirrhotic rats had a marked distortion of the liver parenchyma with abundant fibrosis. Rats receiving RVXB had no (CCl 4 model) or just a mild (-14%; TAA model) and nonsignificant decrease in hepatic fibrosis evaluated by Sirius Red staining (Fig. 3A) . In addition, lower hydroxyproline (Fig. 3B ) and collagen content (by western blotting [ Fig. 3C ] and TEM [ Fig. 3D] ) was observed either in CCl 4 -and TAA-cirrhotic rats. However, this reduction was only significant for collagen protein measured by western blotting in TAA-cirrhotic rats (Fig. 3C, right) . Altogether, these data suggest that the beneficial effect of RVXB was not mainly attributed to a reduced collagen deposition.
RVXB DECREASES AND DEACTIVATES HSCs IN CIRRHOTIC RATS
Treatment with RVXB caused a decrease in desmin expression, a marker of HSCs (-40% by immunohistochemistry [IHC] and -29% by western blotting in CCl 4 -cirrhotic rats; Fig. 4A ). This decrease in HSC number was accompanied with a significant reduction in a-SMA protein levels (-42% by IHC and -60% by western blotting in CCl 4 -cirrhotic rats; Fig. 4B ). To confirm that decrease in a-SMA was not mainly caused by a reduction in the number of HSCs, we isolated HSCs from vehicle-and RVXB-treated CCl 4 -cirrhotic rats. Moreover, there was a significant reduction in gene expression of a-sma (-40%), col1a1 (-80%), and pdgfrb (-52%) in primary HSCs isolated from CCl 4 -cirrhotic rats treated with RVXB (Fig.  4C) . Furthermore, we assessed HSC contractility by means of phosphorylated-moesin, moesin, and RhoA protein expression and observed that RVXB-treated rats had lower expression in CCl 4 -cirrhotic rats (Fig.  4D) . No differences in HSC apoptosis were observed by analyzing cleaved capsase-3 protein expression in isolated HSCs from vehicle-and rivaroxaban-treated CCl 4 -cirrhotic rats (Fig. 4E) . The same results were   FIG. 4 . RVXB decreases and deactivates HSC in CCl 4 -cirrhotic rats. Representative images and desmin protein quantification in livers from CCl 4 -cirrhotic rats treated with vehicle or RVXB by IHC and western blotting (A). Representative images and a-SMA protein quantification of livers described above by IHC and western blotting (B). Expression of the HSC phenotype markers, a-sma, col1a1, and pdgfrb, in HSCs isolated form vehicle-and RVXB-treated CCl 4 -cirrhotic rats (C). RhoA and phospho-moesin/moesin protein expression were analyzed in livers described above (D). Expression of the apoptosis marker, cleaved caspase-3, was analyzed in HSCs isolated from vehicle-and RVXB-treated CCl 4 -cirrhotic rats (E). Values represent mean 6 SEM. Abbreviation: Veh, vehicle.
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observed in TAA-cirrhotic rats. The number of HSCs was decreased in RVXB-treated TAA-cirrhotic rats when analyzed in TEM (-46%; Supporting Fig. S1A) , and a-SMA protein expression was also reduced (vehicle: 1.9 6 0.5 vs. RVXB: 1.0 6 0.2% of area; P 5 0.07; Fig. 5A ). Furthermore, RVXB-treated TAA-cirrhotic rats had significantly lower expression of HSC activation markers a-sma (-54%), col1a1 (-45%), col1a2 (-42%), pdgfrb (-70%), timp1 (-35%), timp2 (-39%), and tgfb (-35%; Fig. 5B ). These results strongly suggest that RVXB deactivates HSCs.
RVXB HAS NO DIRECT EFFECTS ON HSCs
To further study the mechanism of action of RVXB, we evaluated the effects of RVXB and thrombin on HSC activation in isolated HSCs from non-irrhotic rats. First, we observed HSC activation by thrombin (1 and 5 U/mL; 24 hours) by analyzing several HSC activation markers (Supporting Fig. S1 ). However, when we evaluated the direct effects of RVXB, there were no direct effects (Supporting Fig. S2 ), further suggesting that improvement in HSC phenotype attributed to RVXB is mainly the result of inhibition of the coagulation cascade and of PAR-mediated activation, rather than a direct effect of RVXB on HSC.
RVXB DECREASES LIVER MICROTHROMBOSIS IN CIRRHOTIC RATS
RVXB treatment showed a marked and significant decrease in fibrin deposition, a surrogate marker of liver microthrombosis. In fact, RVXB treatment effectively decreased fibrin deposition in CCl 4 - (Fig. 6A) FIG. 5. RVXB decreases and deactivates HSC in TAA-cirrhotic rats. HSC (arrows) quantification and representative images in TAA-cirrhotic rats treated with vehicle or RVXB 30003 (A). a-SMA immunofluorescence in vehicle-and RVXB-treated TAA-cirrhotic rats and quantification (B). Expression of the HSC phenotype markers, a-sma, col1a1, col1a2, pdgfrb, timp1, timp2, and tgfb, in TAA-cirrhotic rats treated with vehicle or RVXB (C). Values represent mean 6 SEM. Abbreviation: Veh, vehicle.
and TAA-cirrhotic rats (Fig. 6B) without causing bleeding events. These findings support a reduction of thrombotic events within the liver of rats treated with RVXB without increased bleeding risk.
Discussion
Current data clearly show that patients with cirrhosis have a hypercoagulative state that may increase the thrombotic risk and contribute to progression of the disease. The increased thrombin generation present in patients with cirrhosis has the potential to keep HSCs activated with the ensuing increase in its capability to secrete ECM deposition and also to increase hepatic vascular tone. (31, 32) These are two major mechanisms increasing hepatic vascular resistance to PBF in cirrhosis and, as a consequence, PH. In addition, several factors, such as blood rheology or increased hypercoagulability, would further increase resistance to PBF. In fact, the latter has been suggested to favor microthrombotic events in the liver microcirculation that, as a consequence of local hepatic ischemia, cause areas of parenchymal extinction leading to tissue collapse and additional microcirculatory dysfunction. (13, 14) Altogether these findings have led us to propose that preventing thrombin action by means of anticoagulants may be a new and effective therapeutic strategy in cirrhosis.
Several studies have shown beneficial effects of inhibiting the coagulation cascade in liver fibrosis (LF). (16, 17) Indeed, we have recently shown benefits of enoxaparin, an LMWH with anti-Xa and thrombin effects, in two different models of cirrhosis. In that study, enoxaparin reduced LF, deactivated HSCs, and decreased hepatic microthrombosis, thereby reducing intrahepatic vascular resistance and PP, (18) confirming positive effects of anticoagulants in severe cirrhosis in preclinical studies. Moreover, a recent randomized trial suggested that long-term LWMH administration not only prevents portal vein thrombosis, but also improves survival in patients with advanced cirrhosis. (33) It is known that patients with cirrhosis have a reduction in antithrombin levels directly related to the degree of liver dysfunction. (34, 35) RVXB, in contrast to a LMWH such as enoxaparin, is an antithrombinindependent inhibitor with highly selective inhibitory action against factor Xa (inhibits both free factor Xa and factor Xa bound in the prothrombinase complex) and therefore its effect is not related to antithrombin levels. Moreover, rivaroxaban has the advantage of oral bioavailability and rapid onset of action. (36, 37) Altogether, these properties make RVXB a more predictable and potentially more efficient anticoagulant compared with heparins. However, the beneficial effect of RVXB in liver cirrhosis has not been investigated so far.
The present study further confirms the beneficial effect of the use of anticoagulants in cirrhosis with PH. Indeed, our study clearly shows that oral administration of RVXB decreases liver oxidative stress, improves NO bioavailability, deactivates HSCs, and reduces PH in two experimental models of cirrhosis.
Reduction in PP caused by RVXB was not associated, in any of the two models of cirrhosis, with significant changes in PBF, suggesting an effective reduction in IHVR. Moreover, when IHVR was evaluated ex vivo in a portal-flow-controlled perfusion system, RVXB-treated CCl 4 -cirrhotic rats had a significantly reduced IHVR, confirming RVXB's effect in decreasing IHVR. Increased IHVR in cirrhosis results from both increased hepatic vascular tone and architectural alterations of the liver. The results of our study suggest that RVXB is probably modifying both components of IHVR.
On one hand, cirrhotic rats receiving RVXB had decreased O 2 -levels, probably attributed to lower inflammatory cell recruitment and lower amounts of HSCs, leading to increased cGMP levels, a surrogate of NO bioavailability, and improved response to incremental doses of Ach. The latter, however, and probably attributed to the high variability, did not reach statistical significance. Nevertheless, vWF expression was much decreased in the liver vasculature of RVXBtreated cirrhotic rats, altogether pointing to an important effect of RVXB in improving liver endothelial dysfunction.
On the other hand, HSCs isolated from RVXBtreated cirrhotic rats showed lower amounts of HSCs and a marked down-regulation of well-recognized molecular markers of HSC activation and proliferation that correlate with their contractile and ECM secretion capability, namely, a-sma, col1, pdgfrb, tgfb, timp1, and timp2. Moreover, we confirmed that the decreased number of HSCs observed in RVXB-treated rats was not attributed to increased apoptosis, but rather reduced proliferation. Because RVXB promoted HSC deactivation, as well as led to HSC relaxation and consequent reduction in IHVR, we evaluated phosphorylated-moesin/moesin and RhoA protein expression in CCl 4 -cirrhotic rats and observed that RVXB-treated rats had lower phospho-moesin/moesin ratio and lower RhoA protein expression, further supporting the effects of RVXB decreasing IHVR.
This effect of RVXB on HSCs was associated with a mild decrease in collagen content in liver tissue, analyzed by hydroxyproline content and collagen protein expression. Nevertheless, we were unable to identify a significant reduction in LF evaluated by Sirius Red staining.
It is tempting to speculate that perhaps longer RVXB treatment may reduce, in a more significant way, LF, in view of the marked reduction in HSC activation achieved. This is further supported by our finding that RVXB had clear beneficial effects on other architectural disturbances of cirrhosis. Analysis by TEM of the liver showed that RVXB-treated cirrhotic rats had less formation of basal membrane in the sinusoids and hepatocytes had more projections than vehicle-treated cirrhotic rats, reflecting improved liver sinusoid assembly. Moreover, in both cirrhotic models, livers from RVXB-treated rats had decreased intrahepatic fibrin deposition.
Remarkably, the beneficial effect of RVXB on PP occurred in the absence of deleterious effects on systemic hemodynamic, as shown by the absence of significant changes in MAP or HR. Similarly, no changes in hematocrit and no bleeding manifestations were detected during treatment.
In conclusion, this study shows that RVXB administration is able to decrease PH in two preclinical models of cirrhosis. This was mainly achieved by improving hepatic vascular resistance by means of a combination of improved liver sinusoid dysfunction, increased NO bioavailability, HSC deactivation, and decreased liver microthrombosis. The net result of these effects was a reduction in PP without negative effects on systemic hemodynamic or bleeding.
